Company logo

JAGX - Jaguar Health, Inc.

NASDAQ -> Healthcare -> Biotechnology
San Francisco, United States
Type: Equity

JAGX price evolution
JAGX
(in millions $) 30 Sep 2022 30 Jun 2022 31 Mar 2022 31 Dec 2021
Current assets
Cash $10.56 $9.01 $17.46 $17.05
Short term investments
Net receivables $2.46 $2.08 $2.25 $2.14
Inventory $6.6 $6.75 $4.88 $4.9
Total current assets $25.21 $23.36 $28.47 $28.43
Long term investments
Property, plant & equipment $1.68 $1.78 $1.76 $1.73
Goodwill & intangible assets $22.56 $22.99 $22.23 $22.65
Total noncurrent assets $26.08 $26.52 $24.43 $24.83
Total investments
Total assets $51.29 $49.88 $52.91 $53.27
Current liabilities
Accounts payable $6.29 $5.64 $3.71 $4.93
Deferred revenue
Short long term debt $12.15 $8.34 $7.19 $3.42
Total current liabilities $26.94 $22.9 $19.09 $15.47
Long term debt $20.74 $24.23 $0.92 $25.94
Total noncurrent liabilities $20.74 $24.23 $25.7 $25.94
Total debt $32.9 $32.57 $8.11 $29.36
Total liabilities $47.69 $47.13 $44.8 $41.41
Shareholders' equity
Retained earnings -$259.37 -$246.85 -$237.48 -$219.49
Other shareholder equity
Total shareholder equity $3.65 $2.72 $8.04 $11.61
(in millions $) 31 Dec 2021 31 Dec 2020 31 Dec 2019 31 Dec 2018
Current assets
Cash $17.05 $8.09 $3.88 $2.57
Short term investments
Net receivables $2.14 $4.56 $1.69 $1
Inventory $4.9 $2.78 $2.13 $3.34
Total current assets $28.43 $17.79 $9.52 $8.15
Long term investments
Property, plant & equipment $1.73 $0.68 $1.26 $0.76
Goodwill & intangible assets $22.65 $24.34 $26.02 $31.71
Total noncurrent assets $24.83 $25.05 $26.89 $32.89
Total investments
Total assets $53.27 $42.84 $36.41 $41.04
Current liabilities
Accounts payable $4.93 $4.76 $5.35 $5.41
Deferred revenue
Short long term debt $3.42 $3.79 $7.12 $16.08
Total current liabilities $15.47 $13.22 $15.39 $26.66
Long term debt $25.94 $12.42 $0.45
Total noncurrent liabilities $25.94 $12.42 $0.45
Total debt $29.36 $16.21 $7.57 $16.08
Total liabilities $41.41 $25.64 $15.84 $26.66
Shareholders' equity
Retained earnings -$219.49 -$166.9 -$133.09 -$94.55
Other shareholder equity $11.61 $9
Total shareholder equity $11.61 $17.2 $10.67 $5.38
(in millions $) 30 Sep 2022 30 Jun 2022 31 Mar 2022 31 Dec 2021
Revenue
Total revenue $3.15 $2.92 $2.63 $2.08
Cost of revenue $0.61 $0.46 $0.46 $0.47
Gross Profit $2.54 $2.46 $2.17 $1.61
Operating activities
Research & development $5.94 $2.45 $4.95 $5.48
Selling, general & administrative $6.49 $6.49 $8.98 $6.95
Total operating expenses $12.43 $8.94 $13.92 $12.43
Operating income -$9.9 -$6.48 -$11.75 -$10.82
Income from continuing operations
EBIT -$9.88 -$6.85 -$13.97 -$11.88
Income tax expense
Interest expense $2.73 $2.54 $4.19 $2.43
Net income
Net income -$12.61 -$9.39 -$18.16 -$14.32
Income (for common shares) -$12.52 -$9.37 -$17.99 -$14.31
(in millions $) 31 Dec 2021 31 Dec 2020 31 Dec 2019 31 Dec 2018
Revenue
Total revenue $4.33 $9.38 $5.78 $4.42
Cost of revenue $2.33 $3.28 $3.82 $2.77
Gross Profit $2 $6.11 $1.96 $1.65
Operating activities
Research & development $15.08 $6.41 $5.82 $5.15
Selling, general & administrative $26 $21 $20.44 $22.11
Total operating expenses $42.71 $32.75 $30.91 $32.47
Operating income -$40.71 -$26.65 -$28.95 -$30.82
Income from continuing operations
EBIT -$44.18 -$31.02 -$32.8 -$29.52
Income tax expense $0.01
Interest expense $8.42 $2.79 $5.73 $2.63
Net income
Net income -$52.6 -$33.81 -$38.54 -$32.15
Income (for common shares) -$52.59 -$38.65 -$44.73 -$32.15
(in millions $) 30 Sep 2022 30 Jun 2022 31 Mar 2022 31 Dec 2021
Net income -$12.61 -$9.39 -$18.16 -$14.32
Operating activities
Depreciation $0.59 $0.65 $0.46 $0.48
Business acquisitions & disposals
Stock-based compensation $0.74 $1.11 $1.06 $1.14
Total cash flows from operations -$8.53 -$10.46 -$7.7 -$8.92
Investing activities
Capital expenditures -$0
Investments $10.48
Total cash flows from investing -$0.06 $10.48
Financing activities
Dividends paid
Sale and purchase of stock $6.22 $2.45 $3.23
Net borrowings $3.88 $0.66 -$0.78 -$0.35
Total cash flows from financing $10.15 $3.25 $8.15 $3.12
Effect of exchange rate -$0.01 $0.03
Change in cash and equivalents $1.55 -$8.44 $0.41 $4.68
(in millions $) 31 Dec 2021 31 Dec 2020 31 Dec 2019 31 Dec 2018
Net income -$52.6 -$33.81 -$38.54 -$32.15
Operating activities
Depreciation $1.81 $2.28 $1.93 $1.32
Business acquisitions & disposals
Stock-based compensation $3.97 $3.81 $3.13 $2.02
Total cash flows from operations -$34.97 -$15.28 -$20.46 -$22.73
Investing activities
Capital expenditures -$0.01 -$0.01 -$0.01
Investments
Total cash flows from investing -$0.01 -$0.01 -$0.01
Financing activities
Dividends paid
Sale and purchase of stock $35.62 $7.76 $6.63 $16.68
Net borrowings $8.11 $12.06 -$0.1 $0.78
Total cash flows from financing $43.94 $19.49 $21.77 $24.55
Effect of exchange rate
Change in cash and equivalents $8.96 $4.21 $1.32 $1.81
Fundamentals
Market cap $624.98M
Enterprise value $647.32M
Shares outstanding 137.96M
Revenue $10.78M
EBITDA -$40.42M
EBIT -$42.59M
Net Income -$54.48M
Revenue Q/Q 400.00%
Revenue Y/Y 123.01%
P/E ratio -11.47
EV/Sales 60.07
EV/EBITDA -16.02
EV/EBIT -15.20
P/S ratio 58.00
P/B ratio 171.37
Book/Share 0.03
Cash/Share 0.08
EPS -$0.39
ROA -105.10%
ROE -837.56%
Debt/Equity 3.57
Net debt/EBITDA -0.92
Current ratio 0.94
Quick ratio 0.69